

#### **Cancer cachexia**

#### -a short overview

Trondheim, 26th November 2021 Tora Skeidsvoll Solheim Consultant oncology/professor palliative care





- Why focus on weight loss?
- What is cachexia and why is it important?
- What is the pathophysiology of cachexia?
- Which interventions are of importance?





### **General malnutrition definition**

- Lack of energy and protein results in weight loss and reduced muscle mass
  - leads to worsened physical or mental function and poorer outcome in case of illness





### In general -Why is malnutrition important in patient care?


- Increased risk of infections
- Reduced muscle strength
  - difficult mobilization, poor coughing power
- Reduced wound healing
  - wound rupture and anastomosis failure
- Psychological functions
  - lethargy, malaise, memory loss, depression, personality changes, apathy and fatigue
- Delayed rehabilitation





# What are the consequences of weight loss in cancer?

- Progressive weight loss interferes with cancer therapy
- Responsible for a poor quality of life and decreased function
- Patients with weight loss live shorter irrespective of tumour mass or the presence of metastasis
- Will often cause significant psychological distress, affecting also patients' next of kin



Det skapende universitet

### **Conclusion:**

- Nutrition and weight are important!
- Think about it early!
  - Ask about food intake and what prevents patients from eating
  - Weight change
  - Physical activity
  - Cancer stage, prognosis and expected effect of tumor treatment
- There are several different tools for screening and diagnostics
  - MUST, NRS-02, MNT, PG-SGA etc





# Cause of weight loss in patients with cancer?

- Symptoms and conditions that reduce food intake
- Reduced gastrointestinal absorption
- Protein loss
- Treatment
- Economics / psychosocial conditions
- Decreased muscle activity
- Cancer related cachexia
- Increased catabolism (e.g. cachexia due to COPD)

















**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM


#### **Definition of cachexia**

- Cancer cachexia is a multidimensional syndrome with on-going muscle loss (and often fat loss)
- It cannot be cured by conventional nutrition alone
- Leads to progressive functional impairment




Fearon K, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncology 2011












**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM



# With the patient in front of you, what is the contribution of cachexia?

Example: Patient with Non Small Cell Lung Cancer




NSCLC receiving RT against trachea Stage IIIb NSCLC receiving chemotherapy


Stage IV NSCLC progressing

Modified from Fearon, Arends, Baracos. Nature Reviews Clinical Oncology 2013





#### Different treatment aims at different stages



ST. OLAVS H

UNIVERSITETSSYKEHUSET I TRONDHEIM

TRONDHEIM K, et al. 2008 NTNU Det skapende universitet

#### Treatment

- No consensus on how to treat cancer cachexia
- Doubtful that major treatment achievements are to be reached using unimodal therapy
  - When we approach a patient loosing weight, think broadly










Inflammation and catabolic changes

Reduced food intake Reduced physical activity


Cancer







### **Complex interventions for cachexia**





**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM


#### **Optimal cancer treatment for all**

- Curing the cancer is still the only way to cure cancer cachexia
  - But, cancer treatment might also increase muscle breakdown





### **Complex interventions for cachexia**





## Symptom management



- It is imperative to treat symptoms or conditions that interfere with nutritional intake
- Perhaps its not mainly cachexia, perhaps the patient is starving?
  - Nausea, pain, bowel obstruction, wrong diet etc





#### Symptom management

- But symptom relief is not always *adding* a pharmacological treatment
- Always keep scrupulous attention to whether the patient really need the prescribed drug – or if the dose can be reduced





#### Symptom management



- A lot of side effects mimic common symptoms in advanced cancer / refractory cachexia
- What drugs do you most commonly consider affecting fatigue/cachexia?
  - Opioids: nausea, constipation, sedation, dry mouth, reduced appetite
  - Benzodiazepam: sedation, dizziness
  - 5-HT3R antagonists: constipation
  - Dipyridamol: dizziness, nausea
  - Statins: headache, difficulty sleeping, muscle aches, drowsiness, dizziness, myopathy





# Symptom management includes communication

Lack of focus on cachexia from

health care professionals is common

- This increases patients' and relatives' confusion, anxiety and concern
- Patients need their weight loss to be acknowledged, need to receive information and to get advice on how to intervene
  - Ref Reid et al 2009



#### Communication

- Both patient and relatives
- Open questions, empathizing, actively listening
- Information on cachexia mechanisms
- Interventions/approach and reasonable goals







#### Information to relatives/patients


#### • How to reply:

- Why do you let my mother starve? She is nothing but skin and bones!!
- Has she decided that she wants to die from me? She does not eat all the good things I make for her!
- How much can I pressure her to eat?
- What can I do for my mother now when I can't support her by giving her treats?





### **Complex interventions for cachexia**





**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM

#### **Nutrition**



- Many cancer patients' dietary intake is insufficient to support energy and protein balance
- Relevant to all cancer patients:
  - Energy requirements: 25-30 kcal/kg/day
  - Protein intake: >1 g/kg/day, if possible up to 1.5 g/kg/day
  - High fat/carbohydrate ratio diet to patients with insulin resistance
  - Vitamins and trace elements supplied equal to RDA
    - ESPEN guidelines 2017: strong recommendation, low and moderate LOE



#### Ernæring

#### • 11 RCT (1981-2015) ONS and/or nutritional advice

All studies		Mean Diff.	Lower CL	Upper CL	Weight (%
Elkort, 1981		-0.34	-5.220	4.540	3.0%
Ovesen, 1993		0.9	-1.100	2 900	10.5%
		3.5	1,444	5.556	10.5%
Breitkreutz, 2005		0.23	-0.613	1.073	17.9%
Baldwin, 2011 (DC vs no DC)					
Bourdel-Marchasson, 2014		-0.3	-1.490	0.880	15.6%
Guarcello, 2007 *	Pir-1	1.845	0.243	3.447	12.8%
Trabal, 2010		6.11	1.241	10.979	3.0%
van der Meij, 2010	H-	1.46	-0.255	3.175	12.1%
Sanchez-Lara, 2014	H-H	1.87	0.585	3.155	14.9%
Random effect REML P=0.0226	++	1.3101	0.238	2.383	
Random effect REMI. Centralized baseline weight adjusted P=0.0269	+ <b>+</b> -	1.316	0.200	2.432	
DC and/or high-energy ONS					
Elkort, 1981		-0.34	-5.220	4.540	6.4%
Ovesen, 1993	<b>⊢</b> ∔−1	0.9	-1.100	2.900	19.3%
Breitkreutz, 2005		3.5	1.444	5.556	18.9%
Baldwin, 2011 (DC vs no DC)	Hà	0.23	-0.613	1.073	29.1%
Bourdel-Marchasson, 2014	F= 1	-0.3	-1.480	0.880	26.3%
Random effect REMIL P=0.3167	H.	0.8001	-1.143	2.743	
High-protein, n-3 PUFA-enriched ONS					
Guarcello, 2007 †		1.845	0.243	3.447	28.3%
Trabal, 2010		6.11	1.241	10.979	3.1%
van der Meij, 2010	(	1.46	-0.255	3.175	24.7%
Sanchez-Lara, 2014	H	1.87	0.585	3.155	44.0%
Random effect REML P=0.0224	⊢ <b>∳</b> ⊣	1.8915	0.508	3.276	
	Controls Interventio	n			

ESTO SCENCE BUTTER HEREALE HEST PRACTICE

REVIEW

Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials

M. A. E. de van der Schueren<sup>1,2\*</sup>, A. Laviano<sup>3</sup>, H. Blanchard<sup>4</sup>, M. Jourdan<sup>4</sup>, J. Arends<sup>5</sup> & V. E. Baracos<sup>6</sup>





Annals of Oncology 29: 1141–1153, 2018 doi:10.1093/annonc/mdy114 Published online 18 April 2018

#### Nutrition

- Intervention in the following order (if indicated):
  - Counselling and use of oral nutritional supplements
  - Enteral nutrition (tube feeding, PEG)
  - Parenteral nutrition





### Nutritional counseling

- Energy dense food
- High in proteins
- Small, appetizing meals
- Increased meal frequency
- People eat more of what they enjoy to eat



- No proven benefit of "A healthy diet" (5 a day fruit and vegetables, high fibers, low fat) in advanced cancer
- ONS



### Nutrition

- Meta analysis (13 studies, 1414 patients):
  - Nutritional intervention associated with
    - Increased energy intake (430Kcal/d)
    - Some weight gain (1.86 kg)
    - Exploratory data suggesting effects on overall quality of life
    - No effect on mortality
      - Ref: Baldwin C, 2012
- New RCT from inpatient cancer patients in Switzerland
  - Standard care vs individualized nutritional support
  - 30 day mortality 14.1% vs 19.9%
    - Ref: Bargetzi L et al. Annals of Oncology 2021



#### Nutrition

 Dietary counselling in advanced cancer makes it possible to maintain or increase energy and protein intake


ref: Balstad et al 2014

- But nutrition alone seems not to be enough





# More «aggressive» nutritional interventions?







#### Sonde-ernæring/intravenøs ernæring

When?





Parenteral nutrition in patients with advanced cancer: Tobberup R et al Crit Rev Oncol hematol 2019

Three small RCTs on the use of IV nutrition in patients with advanced cancer





#### **Medical nutrition**


Some observational studies

Time-points	то	T1	T2	Т3	T4
Number of available	111/111 (100%)	97/111 (87.4%)	76/111 (68.5%)	54/111 (48.6%)	49/111 (44.1%)
measures					
Global QoL <sup>1</sup>	52 (17)	58 (17)	66 (17)	71 (14)	66 (16)
PF <sup>1</sup>	38 (22)	42 (22)	46 (21)	55 (16)	52 (17)
RF <sup>1</sup>	33 (24)	38 (26)	41 (24)	48 (19)	45 (20)
EF <sup>1</sup>	47 (16)	51 (17)	52 (13)	56 (12)	55 (12)
CF <sup>1</sup>	58 (17)	59 (18)	62 (16)	62 (17)	63 (12)
SF <sup>1</sup>	53 (21)	54 (20)	56 (21)	60 (16)	57 (21)
AP <sup>2</sup>	79 (26)	77 (23)	74 (22)	63 (26)	64 (24)
FA <sup>2</sup>	77 (17)	75 (16)	73 (17)	73 (18)	71 (16)
NV <sup>2</sup>	56 (25)	52 (20)	54 (20)	54 (18)	54 (20)
FI <sup>2</sup>	36 (21)	36 (19)	36 (19)	34 (15)	35 (16)





### **Medical nutrition**



 Current parenteral nutrition treatment in patients with advanced cancer is understudied and the level of evidence is weak

- Tobberup et al, Crit Rev Oncol Hematol, 2019

- Conflicting guidelines and not much evidence for the effect of intravenous or enteral nutritional treatment
  - Varying clinical practice

•••• ST. OLAVS HOSPITAL UNIVERSITETSSYKEHUSET I TRONDHEIM



Supportive Care in Cancer https://doi.org/10.1007/s00520-021-06613-y

**REVIEW ARTICLE** 



#### Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer

 $\label{eq:Bryony Alderman} \begin{array}{l} {}^{1} \cdot {\rm Lindsey \, Allan}^{1} \cdot {\rm Koji \, Amano}^{2} \cdot {\rm Carole \, Bouleuc}^{3} \cdot {\rm Mellar \, Davis}^{4} \cdot {\rm Stephanie \, Lister-Flynn}^{5} \cdot {\rm Sandip \, Mukhopadhyay}^{6} \cdot {\rm Andrew \, Davies}^{7,8,9} \\ \end{array}$ 

Received: 1 September 2021 / Accepted: 3 October 2021 © The Author(s) 2021

**Results** The Subgroup produced 11 suggestions, and 1 recommendation (due to the paucity of evidence). These outcomes relate to assessment of patients, indications for CAN, contraindications for CAN, procedures for initiating CAN, and re-assessment of patients.

**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM



#### Case 1

- 65 Year old woman with metastatic breast cancer, gradually developed ileus, medically treated. Weight loss 20% last 6 months, fatigue, is in bed or in a chair 50% of the day.
- How many would give intravenous nutrition?
- For how long time would you give it?





#### Case 2

- 35 year old male with aggressive metastatic sarcoma, rapidly developing disease without more tumor treatment available. CRP 65 without infection, albumin 29.
- In bed > 50% of the day. Weight loss 10% last 6 months. No gastrointestinal obstruction.
- Appetite loss, last weak he has eaten less than 60% of required calculated calories.
- How many would recommend medical nutrition?






#### Case 3

- 73 year old man with metastatic prostate cancer on 3<sup>rd</sup> line treatment
- 10% weight loss developed gradually last year. No nutritional impact symptoms but appetite loss, and has eaten less than 60% of required calculated calories
- Conflict in family, patients think the situation is OK, relatives terrified because of the weight loss
- Would you give medical nutritional treatment?





#### **Complex interventions for cachexia**





**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM

#### Exercise

- Potential effect:
  - Inhibition of inflammation, increase anabolism
  - Prevents inactivity-induced sarcopenia
  - Better quality of life, fatigue and muscle mass



- Evidence:
  - Despite strong clinical rationale, not enough studies have been conducted to assess efficacy in patients with cachexia
    - Grande AJ 2015, Cochrane Collaboration systematic review
- Exercise can improve QoL and relieve fatigue, insomnia, dyspnoea and physical and social functioning for patients with advanced cancer
  - Ya-jing Chen 2020, Systematic review and meta-analysis (15 RCTs, 1208 patients)





#### **Physical exercise**

- How?
- What "dose"?

















#### **Complex interventions for cachexia**





**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM



#### Pharmacological symptom relief in refractory cachexia – most important agents

- Only progestins and corticosteroids were found to have sufficient evidence to support their use in improvement of appetite
  - Ref:Yavuzsen 2005







#### Progestines

- RR appetite improvement: 2.57 (1.48-4.49)
- RR weight improvement: 1.55 (1.08-2.26)
- Increased risk; impotence, dyspnoea, oedema, thromboembolism

Ref: Ruiz Garcia V et al 2005, 2013, and 2018

- Optimal dose is 160-800 mg/d (?)
- For short-intermediate term appetite stimulation and increase of weight but not muscle mass





#### Corticosteroids


- Can improve QoL, appetite, vomiting, wellbeing, fatigue
   Weight is often not significantly affected
- Side effects: myopathy, hyperglycemia, mood changes and immunosuppression
- For short duration (1-2 weeks), improvement in appetite





#### Metoclopramide

- Fewer patients included in studies
- Can help in patients with early satiety, chronic gastro paresis and nausea





• ST. OLAVS HOSPITAL UNIVERSITETSSYKEHUSET I TRONDHEIM


### **Upcoming drugs?**

- Anamorelin (Ghrelin-analogue)
- Enobosarm (selective androgen receptor modulator)
- Other
  - Cannaboinoids, androgens, olanzapine, fometerol, NSAID..





#### **Complex interventions for cachexia**





**ST. OLAVS HOSPITAL** UNIVERSITETSSYKEHUSET I TRONDHEIM

#### **Complex interventions**

- Observational data from cachexia clinics show some benefit in programs treating symptoms impeding food intake, recommending exercise and give nutritional advice
  - Ref: Del Fabbro et al (2011). Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. Parmar et al . (2013). Weight changes correlate with alterations in subjective physical function in advanced cancer patients referred to a specialized nutrition and rehabilitation team.
- Feasibility study (preMENAC) shows that complex intervention is feasible and that patients are willing to participate
  - Solheim et al. 2017






Clinical Nutrition 40 (2021) 2898-2913



ESPEN Guideline

ESPEN practical guideline: Clinical Nutrition in cancer

Maurizio Muscaritoli <sup>a, \*</sup>, Jann Arends <sup>b</sup>, Patrick Bachmann <sup>c</sup>, Vickie Baracos <sup>d</sup>, Nicole Barthelemy <sup>e</sup>, Hartmut Bertz <sup>b</sup>, Federico Bozzetti <sup>f</sup>, Elisabeth Hütterer <sup>g</sup>, Elizabeth Isenring <sup>h</sup>, Stein Kaasa <sup>i</sup>, Zeljko Krznaric <sup>j</sup>, Barry Laird <sup>k</sup>, Maria Larsson <sup>1</sup>, Alessandro Laviano <sup>a</sup>, Stefan Mühlebach <sup>m</sup>, Line Oldervoll <sup>n</sup>, Paula Ravasco <sup>o</sup>, Tora S. Solheim <sup>p</sup>, Florian Strasser <sup>q</sup>, Marian de van der Schueren <sup>r, s</sup>, Jean-Charles Preiser <sup>t</sup>, Stephan C. Bischoff <sup>u</sup>





#### Guidelines

### Guidelines





SPECIAL ARTICLE

Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines  $\stackrel{\star}{\approx}$ 

J. Arends<sup>1</sup>, F. Strasser<sup>2,3</sup>, S. Gonella<sup>4,5</sup>, T. S. Solheim<sup>6,7</sup>, C. Madeddu<sup>8</sup>, P. Ravasco<sup>9,10,11</sup>, L. Buonaccorso<sup>12</sup>, M. A. E. de van der Schueren<sup>13,14</sup>, C. Baldwin<sup>15</sup>, M. Chasen<sup>16,17,18</sup> & C. I. Ripamonti<sup>19</sup>, on behalf of the ESMO Guidelines Committee<sup>\*</sup>

**Cachexia treatment requires a multimodal approach** aimed at relieving symptoms impacting on food intake, ensuring adequate energy and nutrient intake, minimising catabolic alterations, supporting muscle training and offering psychological and social support [II, B].





#### Guidelines

#### Management of Cancer Cachexia: ASCO Guideline

Eric J. Roeland, MD<sup>1</sup>; Kari Bohlke, ScD<sup>2</sup>; Vickie E. Baracos, PhD<sup>3</sup>; Eduardo Bruera, MD<sup>4</sup>; Egidio del Fabbro, MD<sup>5</sup>; Suzanne Dixon, MPH, MS, RD<sup>6</sup>; Marie Fallon, MD<sup>7</sup>; Jørn Herrstedt, MD, DMSci<sup>8</sup>; Harold Lau, MD<sup>9</sup>; Mary Platek, PhD, MS, RD<sup>10</sup>; Hope S. Rugo, MD<sup>11</sup>; Hester H. Schnipper, LICSW, BCD, OSW-C<sup>12</sup>; Thomas J. Smith, MD<sup>13</sup>; Winston Tan, MD<sup>14</sup>; and Charles L. Loprinzi, MD<sup>15</sup>

**Recommendation 1.1.** Clinicians may refer patients with advanced cancer and loss of appetite and/or body weight to a registered dietitian for assessment and counseling, with the goals of providing patients and caregivers with practical and safe advice for feeding; education regarding high-protein, high-calorie, nutrient-dense food; and advice against fad diets and other unproven or extreme diets (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 2.1.** Evidence remains insufficient to strongly endorse any pharmacologic agent to improve cancer cachexia outcomes; clinicians may choose not to offer medications for the treatment of cancer cachexia. There are currently no FDA-approved medications for the indication of cancer cachexia (Type of recommendation: evidence based; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 3.** Outside the context of a clinical trial, no recommendation can be made for other interventions, such as exercise, for the management of cancer cachexia.





## Summary: For refractory cachexia consider

- Other reasons/contributing factors for weight loss
- Appetizing food/ONS and physical activity in a setting that does not cause distress and does not give false hope or goals
- Communication/information
- Corticosteroids for 1-2 weeks
- Progesteron short time for improving appetite





#### Very advanced terminal phase

- Treatment based on comfort:
  - Artificial hydration and nutrition are unlikely to provide any benefit for most patients
  - Food and artificial nutrition may have social, emotional and existential significance for the individual patient and family members





#### Cachexia - why is it important?

#### • Neglection of cachexia:

- No treatment of reversible causes
- No multimodal approach to counteract complex patophysiology (nutrition, pharmacology, exercise, information)

#### Overtreatment:

- To "aggressive" nutrition
- Family/patient misunderstands cachexia mechanisms
- Lack of alternative intervention to deal with hope, dignity and closure







#### **Patient history**

- **Presentation**: 55 years, 94 kg, 178 cm; married, 2 children engineer in appliance company, hobbies: golf (uses golf cart)
- Medical History: Hypertension (2 drugs), COPD GOLD grade 2, group B, smoking history 30 pack years
   Last two months anorexia, fatigue, more coughing.
- Radiology: Chest X-ray: right hilar lesion; ultrasound: pleural effusion 4 cm. CT chest/abdomen: 4 cm tumor, ipsilateral mediastinal lymph nodes 2 cm no distant metastases





#### **Patient history**

- Bronchoscopy and cytology: Adeno carcinoma, pleural effusion positive for tumor cells
- **Diagnosis**: Non small cell lung cancer, adenocarcinoma, stage IV (cT2a cN2 cM1a)
- Further typing: No driver mutations
- **MDT**: ECOG 1, palliative chemotherapy (carboplatin + pemetrexed)





#### **Q1. What should be the next step?**

- 1. Proceed directly to oncologic treatment
- 2. Explain that fortunately no nutritional risks are to be considered
- 3. Perform screening for, and if necessary assessment, of malnutrition
- 4. Initiate obesity program to reduce body weight
- (one answer)





#### **Q1. What should be the next step?**

- 1. Proceed directly to oncologic treatment
- 2. Explain that fortunately no nutritional risks are to be considered
- 3. Perform screening for and if necessary assessment of malnutrition
- 4. Initiate obesity program to reduce body weight
- (one answer)





#### **Q2. How to screen for Malnutrition?**

- 1. Ask for weight loss during last 3 months.
- 2. Ask for food intake as compared to usual amount.
- 3. Calculate Body Mass Index (WT/HT<sup>2</sup>).
- 4. Ask for physical performance
- 5. All of the above
- (one answer)





#### **Q2. How to screen for Malnutrition?**


- 1. Ask for weight loss during last 3 months.
- 2. Ask for food intake as compared to usual amount.
- 3. Calculate Body Mass Index (WT/HT<sup>2</sup>).
- 4. Ask for physical performance
- **5.** All of the above ( $\rightarrow$  use screening tool, e.g. NRS = Nutrition Risk Screening)
- (one answer)





#### SCREENING


					Nutrition Risk Screening. Kondrup et al., Clin Nutr 2013
	Nutritional status			Age	Severity of disease (≈ metabolic stress)
Points	Food intake	Weight loss	BMI (kg/m²)		
	% of norma	llast 3 months	s if PS>1		
1	50-75%	>5%		≥70 y	Chronic disease ( <b>oncology</b> , diabetes,) Severely acute ill (pneumonia, stroke, <b>hematologic</b> <b>malignancy</b> ,) Intensive care (sepsis,bone marrow transplant,)
2	25-50%	>7.5%	18.5-20.5		
3	0-25%	>15%	<18.5		







#### SCREENING





#### **Q3. How to ASSESS for Malnutrition?**

- 1. Ask for nutrition impact symptoms, e.g. nausea, early satiety
- 2. Estimate food intake
- 3. Assess degree of systemic inflammation
- 4. Measure muscle mass
- 5. All of the above
- (one answer)





#### **Q3. How to ASSESS for Malnutrition?**

- 1. Ask for nutrition impact symptoms, e.g. nausea, early satiety
- 2. Estimate food intake
- 3. Assess degree of systemic inflammation
- 4. Measure muscle mass
- 5. All of the above
- (one answer)





#### Assessment of nutritional status

- <u>Performed by nutrition expert</u>
- Nutrition impact symptoms:
- Food diary:
- Body composition:
- Performance status:
- •
- Metabolism:

anorexia, early satiety

1750 kcal (70%) BMI 30 kg/m<sup>2</sup>, weight loss 8% muscle mass (AMA) 27 kg (sarcopenia) ECOG PS=1 (some 2 hours rest required

during day) systemic inflammation, CRP 60mg/l, albumin 34 g/l





## Q4. WHAT NUTRITIONAL SUPPORT SHOULD THE PATIENT RECEIVE?

- 1. None at this time
- 2. Parenteral nutrition with high fat ratio
- 3. *Glucocorticosteroids* to improve appetite
- 4. *Melatonin* to improve appetite
- 5. Nutritional advice to increase calorie and protein intake
- 6. Consider *metoclopramide* to see if this reduces early satiety
- 7. Consider oral Nutritional Supplements (ONS)
- 8. Advice on individualised *exercise training*
- 9. Options 5-8





## Q4. WHAT NUTRITIONAL SUPPORT SHOULD THE PATIENT RECEIVE?

- 1. None at this time
- 2. Parenteral nutrition with high fat ratio
- 3. *Glucocorticosteroids* to improve appetite
- 4. *Melatonin* to improve appetite
- 5. Nutritional advice to increase calorie and protein intake
- 6. Consider *metoclopramide* to see if this reduces early satiety
- 7. Consider oral Nutritional Supplements (ONS)
- 8. Advice on individualised *exercise training*
- 9. Options 5-8





#### Patient history

- The patients receives chemotherapy (carboplatin / pemetrexed)
- The oncology team have focus on NIS, and he has relatively few challenges with pain and nausea
- He continues golfing, but more often walk than take the cart
- He manages to increase energy and protein intake with the help of protein- and *n*-3 PUFA-enriched ONS, and the weight stabilizes (94kg)
- After 4 cycles of chemotherapy evaluation shows PR, 2 more cycles given





#### Patient history

- After 6 cycles chemotherapy patient is assigned to follow-up
  - During follow-up he starts to develop pain in his back
  - MRI presents several metastatic bone lesions, but one large affecting medulla in TH1
  - Radiotherapy is offered and started, subsequent systemic therapy is planned
  - Halfway through radiotherapy he starts to get pain when swallowing, he feels very tired and anxious, ECOG PS 2



#### **Q5. What should be the next step?**

- Assessment of weight, nutritional intake and other nutritional impact symptoms
- Nutritional advice to increase energy and protein intake
- ONS
- Symptomatic treatment (pain, psychological support)
- All of the above





#### **Q5. What should be the next step?**

- Assessment of weight, nutritional intake and other nutritional impact symptoms
- Nutritional advice to increase energy and protein intake
- ONS
- Symptomatic treatment (pain, psychological support)
- All of the above





#### Patient history

- After radiotherapy the patient is started on immunotherapy (nivolumab)
- His weight is 86 kg and he eats 60% of estimated requirement
- He receives pain treatment, psychological contact as well as nutritional counselling and ONS
- Weight remains stable
- Follow-up at 2 and 4 months shows only minor progress at some locations





#### Patient history

- 6 months into nivolumab treatment..
- .. the patients starts to lose weight again, appetite decreases
- Nutritional intake is less than 40% even after nutritional counselling and ONS
- The patient and his close family are very preoccupied with his lack of food intake and they all are very distressed by this
- Evaluation shows progressive disease in liver and lung, PS 2, weight 80 kg





# Q6: What could BE a possible next step?

• The patient and his family receive renewed information on cancer cachexia and weight loss mechanisms.

Consider a trial with:

- 1. Corticosteroids
- 2. Cannabinoids
- 3. NSAID
- 4. Testosteron
- 5. Parenteral or enteral nutrition





# Q6: What could BE a possible next step?

• The patient and his family receive renewed information on cancer cachexia and weight loss mechanisms.

Consider a trial with:

- 1. Corticosteroids
- 2. Cannabinoids
- 3. NSAID
- 4. Testosteron
- 5. Parenteral or enteral nutrition





### PATIENT HISTORY

- Parenteral nutrition is initiated (gradually increased to 30 kcal/kg/day) and delivered at home during the night, an agreement is made to evaluate the treatment in 2 weeks, and then at given intervals after that
  - The patient feels strongly about parenteral nutrition and will not accept a nasogastric tube
- The patient is started on weekly docetaxel treatment for his lung cancer





#### Patient history

- After 8 weeks of docetaxel treatment he has rapid clinical decline
- CT shows further progressive disease
- PS 3, weight 75 kg
- He is getting ascites and is bothered by his swollen feet
- He would like to get to celebrate his daughters wedding in a neighboring town in the weekend





#### **Q7: What should the next step be**

- 1. Increase parenteral nutrition to 40 kcal/kg/day
- 2. Stress that it is important that he should eat more if he would like to live longer
- 3. Ask him to do exercises to get fit for his daughters wedding
- 4. After discussions with patients and his family, terminate parenteral nutrition and give him a short trial of glucocorticoids
- 5. Start high dose progestins






#### **Q7: What should the next step be**

- 1. Increase parenteral nutrition to 40 kcal/kg/day
- 2. Stress that it is important that he should eat more if he would like to live longer
- 3. Ask him to do exercises to get fit for his daughters wedding
- 4. After discussions with patients and his family, terminate parenteral nutrition and give him a short trial of glucocorticoids
- 5. Start high dose progestins





#### Thank you for your attention





••• ST. OLAVS HOSPITAL UNIVERSITETSSYKEHUSET I TRONDHEIM